<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124162</url>
  </required_header>
  <id_info>
    <org_study_id>30272</org_study_id>
    <nct_id>NCT01124162</nct_id>
  </id_info>
  <brief_title>Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of losartan 100
      mg tablets (test) versus Cozaar® (reference), administered as 1 * 100 mg tablet under fasting
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA Bioequivalence Statistical Methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)</measure>
    <time_frame>Blood samples collected over a 24 hour period.</time_frame>
    <description>Bioequivalence based on Losartan Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</measure>
    <time_frame>Blood samples collected over a 24 hour period.</time_frame>
    <description>Bioequivalence based on Losartan AUC0-t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)</measure>
    <time_frame>Blood samples collected over a 24 hour period.</time_frame>
    <description>Bioequivalence based on Losartan AUC0-inf.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)</measure>
    <time_frame>Blood samples collected over a 24 hour period.</time_frame>
    <description>Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</measure>
    <time_frame>Blood samples collected over a 24 hour period.</time_frame>
    <description>Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Infinity)</measure>
    <time_frame>Blood samples collected over a 24 hour period.</time_frame>
    <description>Informational comparison of AUC0-inf values for the metabolite Losaran Carboxy Acid.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Generic Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 100mg Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cozaar® 100 mg Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>100 mg Tablet</description>
    <arm_group_label>Generic Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cozaar®</intervention_name>
    <description>100 mg Tablet</description>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <other_name>Losartan (generic name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-child-bearing potential female or male.

          -  Non-smoker.

          -  18 years of age and older.

          -  Capable of consent.

          -  Non-child-bearing potential female subject:

               -  Post-menopausal state: absence of menses for 12 months prior to drug
                  administration.

               -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at
                  least 6 months prior to drug administration.

        Exclusion Criteria:

          -  Clinically significant illness within 4 weeks prior to the administration of the study
             medication.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive urine drug screen at screening.

          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or
             over 100 bpm) at screening.

          -  Subjects with BMI &gt; 30.0.

          -  History of significant alcohol abuse within 6 months prior to screening visit or any
             indication of the regular use of more than 14 units of alcohol per week (1 unit = 150
             mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months prior to screening visit or hard drugs (such as cocaine, phencyclidine
             [PCP], and crack) within 1 year prior to the screening visit.

          -  History of allergic reactions to losartan or other related drugs.

          -  History of allergic reactions to heparin.

          -  Use of any drugs known to induce or inhibit drug metabolism within 30 days prior to
             administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowl diseases),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism, or excretion of the study drug.

          -  Any clinically significant history or presence of clinically significant neurological,
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or
             metabolic disease.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products (including natural food supplements, vitamins,
             garlic as a supplement) within 7 days prior to administration of study medication,
             except for topical products without systemic absorption.

          -  Positive alcohol breath test at screening.

          -  Subjects who have used tobacco in any form within 90 days preceding study drug
             administration.

          -  Any food allergy, intolerance, restriction, or special diet that could, in the opinion
             of the Medical Sub-Investigator, contraindicate the subjects participation in this
             study.

          -  A dept injection or an implant of any drug within 3 months prior to administration of
             study medication.

          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or
             loss of whole blood prior to administration of the study medication as follows:

               -  Less than 300 mL of whole blood within 30 days

               -  300 mL to 500 mL of whole blood within 45 days, or

               -  more than 500 mL of whole blood within 56 days prior to drug administration.

          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or frozen)
             within 7 days prior to administration of the study medication.

          -  Clinically significant history of known active hypotension or volume depletion.

          -  Intolerance to venipuncture.

          -  Clinically significant history of renal, hepatic, or cardiovascular disease,
             tuberculosis, epilepsy, asthma, diabetes, psychosis, or glaucoma will not be eligible
             for this study.

          -  Subjects unable to understand or unwilling to sign the Informed Consent Form.

          -  Additional exclusion criteria for females only;

               -  Breast-feeding subjects.

               -  Positive urine pregnancy test at screening (performed for all females).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <results_first_submitted>June 21, 2010</results_first_submitted>
  <results_first_submitted_qc>June 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2010</results_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Associate Director, Biopharmaceutics</name_title>
    <organization>Teva Pharmaceuticals USA</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan (Test) First</title>
          <description>100 mg Losartan Tablets test product dosed in first period followed by 100 mg Cozaar® Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="P2">
          <title>Cozaar® (Reference) First</title>
          <description>100 mg Cozaar® Tablets reference product dosed in first period followed by 100 mg Losartan Tablets test product dosed in the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout of 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan (Test) First</title>
          <description>100 mg Losartan Tablets test product dosed in first period followed by 100 mg Cozaar® Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="B2">
          <title>Cozaar® (Reference) First</title>
          <description>100 mg Cozaar® Tablets reference product dosed in first period followed by 100 mg Losartan Tablets test product dosed in the second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)</title>
        <description>Bioequivalence based on Losartan Cmax.</description>
        <time_frame>Blood samples collected over a 24 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>100 mg Losartan Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Cozaar®</title>
            <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)</title>
          <description>Bioequivalence based on Losartan Cmax.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637.01" spread="340.35"/>
                    <measurement group_id="O2" value="582.39" spread="327.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level.</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>108.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.43</ci_lower_limit>
            <ci_upper_limit>120.03</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</title>
        <description>Bioequivalence based on Losartan AUC0-t.</description>
        <time_frame>Blood samples collected over a 24 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>100 mg Losartan Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Cozaar®</title>
            <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</title>
          <description>Bioequivalence based on Losartan AUC0-t.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="950.90" spread="422.61"/>
                    <measurement group_id="O2" value="934.24" spread="418.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level.</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>101.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.57</ci_lower_limit>
            <ci_upper_limit>104.93</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)</title>
        <description>Bioequivalence based on Losartan AUC0-inf.</description>
        <time_frame>Blood samples collected over a 24 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>100 mg Losartan Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Cozaar®</title>
            <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)</title>
          <description>Bioequivalence based on Losartan AUC0-inf.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="962.67" spread="423.97"/>
                    <measurement group_id="O2" value="947.18" spread="419.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level.</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>101.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.41</ci_lower_limit>
            <ci_upper_limit>104.68</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)</title>
        <description>Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.</description>
        <time_frame>Blood samples collected over a 24 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>100 mg Losartan Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Cozaar®</title>
            <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)</title>
          <description>Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="658.17" spread="272.35"/>
                    <measurement group_id="O2" value="647.22" spread="259.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level.</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>102.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.24</ci_lower_limit>
            <ci_upper_limit>106.06</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</title>
        <description>Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.</description>
        <time_frame>Blood samples collected over a 24 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>100 mg Losartan Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Cozaar®</title>
            <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</title>
          <description>Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3748.87" spread="1314.68"/>
                    <measurement group_id="O2" value="3750.39" spread="1312.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level.</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>100.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.84</ci_lower_limit>
            <ci_upper_limit>102.84</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Infinity)</title>
        <description>Informational comparison of AUC0-inf values for the metabolite Losaran Carboxy Acid.</description>
        <time_frame>Blood samples collected over a 24 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>100 mg Losartan Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Cozaar®</title>
            <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf of Losartan Carboxy Acid(Area Under the Concentration-time Curve From Time Zero to Infinity)</title>
          <description>Informational comparison of AUC0-inf values for the metabolite Losaran Carboxy Acid.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3855.02" spread="1345.50"/>
                    <measurement group_id="O2" value="3858.92" spread="1352.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level.</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>100.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.87</ci_lower_limit>
            <ci_upper_limit>102.69</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.</time_frame>
      <desc>Volunteers were monitored throughout the study for any adverse experiences. AEs were collected through both solicited and unsolicited methods. The volunteers were encouraged to report signs, symptoms, and any changes in health to the clinic staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>100 mg Losartan Tablets test product dosed in either period.</description>
        </group>
        <group group_id="E2">
          <title>Cozaar®</title>
          <description>100 mg Cozaar® Tablets reference product dosed in either period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Low Blood Pressure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals, USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

